Phase 3 Heart Disease Trial, Recruiting NCT06630923 Sponsor: Democritus University of Thrace Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT06630923
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who are experiencing a sudden worsening of chronic heart failure (CHF)
  • People who have signs of liver problems, shown through blood tests or a liver ultrasound
  • People who have a history of chronic heart failure and have previously taken a type of water pill (loop diuretic) by mouth
  • People who are expected to need diuretic treatment given through a drip (IV) for at least 72 hours
  • There is no requirement related to how well the heart is pumping (ejection fraction)

Who may not be able to join:

  • People experiencing cardiovascular collapse, which includes very low blood pressure (below 90 mmHg), a sudden large drop in blood pressure lasting 15 minutes or more with signs of poor blood flow to organs, a need for certain heart-strengthening medications (not including digoxin), or a need for CPR
  • People whose liver problems are caused by something other than heart failure
  • People with severe anaemia (very low red blood cell levels, specifically haemoglobin below 8 g/dL)
  • People with very high blood pressure that is not under control, or a blood pressure emergency
  • People with severe fluid build-up in the lungs that requires medication through a drip (IV vasodilators) to manage
  • People with significantly reduced kidney function, shown by certain blood test results (creatinine above 3 mg/dL or a kidney filtration rate below 30 ml/min)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: MARIOS VASILEIOS KOUTROULOS, University Hospital of Alexandroupolis

Phone: +30 6942862493

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Democritus University of Thrace
Registry
ClinicalTrials.gov
Start date
14 January 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Assessment of symptoms; Change in the serum creatinine level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov